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Abstract
Objective: The mechanism of atherosclerotic plaque progression leading to instability, rupture, and ischemic
manifestation involves oxidative stress and apoptosis. Humanin (HN) is a newly emerging endogenously expressed
cytoprotective peptide. Our goal was to determine the presence and localization of HN in carotid atherosclerotic
plaques.
Methods and Results: Plaque specimens from 34 patients undergoing carotid endarterectomy were classified according to
symptomatic history. Immunostaining combined with digital microscopy revealed greater expression of HN in the unstable
plaques of symptomatic compared to asymptomatic patients (29.4262.05 vs. 14.1462.13% of plaque area, p,0.0001).
These data were further confirmed by immunoblot (density of HN/b-actin standard symptomatic vs. asymptomatic
1.3260.14 vs. 0.7960.11, p,0.01). TUNEL staining revealed a higher proportion of apoptotic nuclei in the plaques of
symptomatic patients compared to asymptomatic (68.2563.61 vs. 33.4664.46% of nuclei, p,0.01). Double immunoflu-
orescence labeling revealed co-localization of HN with macrophages (both M1 and M2 polarization), smooth muscle cells,
fibroblasts, and dendritic cells as well as with inflammatory markers MMP2 and MMP9.
Conclusions: The study demonstrates a higher expression of HN in unstable carotid plaques that is localized to multiple cell
types within the plaque. These data support the involvement of HN in atherosclerosis, possibly as an endogenous response
to the inflammatory and apoptotic processes within the atheromatous plaque.
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Introduction
Atherosclerosis is a progressive and inflammatory disease
characterized by well-defined lipid plaques commonly associated
with necrotic cores, calcified regions, and inflammatory cells [1].
Infiltrating smooth muscle cells, fibroblasts, and immune cells
(notably macrophages but also dendritic cells, T and B cells,
neutrophils, and mast cells) are involved in plaque progression and
destabilization [2,3,4,5].
Cellular apoptosis occurs within the atheroma and is well-
documented yet its role is not fully understood. A number of
proapoptotic factors are documented including reactive oxygen
species (ROS) oxidant stress, oxidized low-density lipoprotein (Ox-
LDL), elevated TNF-a, activation of Fas ligand, and endoplasmic
reticulum stress [6,7,8,9]. Ultimately, apoptosis is characteristic of
plaque progression and leads to instability, rupture, and
subsequent clinical manifestation [10,11,12]. Thus, inhibition of
the apoptotic process may lead to slowing or reversal of
atheromatous plaque development [13].
Humanin (HN) is a 24-amino acid peptide encoded by
mitochondrial 16S rRNA that was first discovered upon isolation
from the occipital lobe of a patient with Alzheimer’s disease
[14,15]. It was found to protect against neuronal apoptotic insult,
specifically against amyloid-b toxicity and several familial disease-
causing mutations [16,17]. This protein has been shown to play a
role in preventing cell death among various tissues outside of the
nervous system as well [18,19,20,21,22]. We have recently
demonstrated that HN is expressed in the endothelium of multiple
vascular beds in humans and that its administration ex vivo results
in decreased ROS production and apoptosis after oxidized LDL
exposure in human aortic endothelial cells, a common inciting
event in formation of the atherosclerotic plaque [20]. Moreover,
we have demonstrated that HN exerts a protective effect on
endothelial function and atherosclerotic progression in Apo E-
deficient mice [23]. Thus, HN may play a protective role in
atherosclerosis. The goal of this study was to test the hypotheses
that HN is present in the atherosclerotic plaque in humans with
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31065expression correlating to apoptosis and symptomatic clinical
presentation and whether it is localized to specific cell types.
Methods
Patients
This study was approved by the Mayo Foundation Institutional
Review Board. Procedures were followed by institutional guide-
lines and written informed consent was obtained before surgery
from all participants.
We studied 34 plaque specimens from patients undergoing
carotid endarterectomy as previously described [8,24,25]. Surgical
intervention was based on present clinical guidelines with the use
of carotid artery imaging (ultrasound defining stenosis at 70–99%;
magnetic resonance angiography defining 80–90% as severe and
90–99% as critical). Demographic data was obtained on all the
patients by chart review with attention to cerebral ischemic events,
coronary artery disease (CAD) risk factors, and medications. CAD
was defined on the basis of a history of angina, myocardial
infarction, coronary artery bypass graft, or percutaneous translu-
minal coronary angioplasty. Patients were deemed symptomatic if
they showed a cerebral ischemic event 120 days prior to the
surgery ipsilateral to the side of the collected plaque [26]. This
included those with prior ischemic stroke (a neurologic episode
lasting more than 24 hours) and transient ischemic attack (TIA, a
reversible neurologic episode lasting less than 24 hours including
amaurosis fugax). Patients having multiple events were categorized
on the basis of their most severe event. Classification of
asymptomatic patients was based on the absence of previous
cerebral ischemic events.
Carotid plaque specimens
After surgical excision, the plaques were cut in half at the site of
maximal diameter. One half was fixed in formalin and embedded
in paraffin for histology; the other half was immediately frozen and
stored at 280uC for later tissue analysis [24,25].
Immunostaining for HN
Paraffin-embedded carotid plaques were immunostained ac-
cording to protocol previously described, using double affinity
purified rabbit anti-HN, developed at UCLA, in a concentration
of 1 mg/mL [20,25]. Normal rabbit immunoglobulin serum
fractions were used as a negative control and testicular biopsy
tissue served as a positive control [18,20].
All stained specimens were sent to a Tissue and Cell Molecular
Analysis core for scanning and conversion to digital microscopic
images (Hamamatsu NanoZoomer Digital Pathology scanning
microscope). These were computationally analyzed and quantified
blindly as the percentage of stained area within the entire section
using Olympus WebSlide Enterprise and Metamorph Meta
Imaging Series 6.1 software.
Western blotting for HN
Frozen tissue samples were prepared and analyzed by Western
Blot as previously described [8,25,27]. Because HN is a very small
peptide, we used a modified protocol in order to achieve band
separation for radiographic densitometry. Carotid lysates were
analyzed for protein content by Bradford Assay (Bio-Rad, CA).
Equal amounts of protein were diluted in lysis buffer and reducing
SDS loading buffer and resolved in a 16.5% Tris-Tricine SDS-
polyacrylamide gel. Electrotransfer to nitrocellulose membrane
was performed followed by blocking with 2% BSA/2% fat-free dry
milk in TBS-T. Membranes were immunoblotted to detect HN
(rabbit anti-HN, Abcam, 1:500), then washed and incubated with
secondary antibody conjugated to horseradish peroxidase (goat
anti-rabbit IgG (H+L), Abcam, 1:5000). A HN protein standard
(CPC Scientific, CA) was run with the samples to correctly identify
target bands and b-actin (rabbit anti-b-actin, Imgenex, 1:5000)
was used as an internal standard for protein loading. After
development of the membranes with chemiluminescence (Thermo
Scientific, IL) and exposure to X-ray film with a UVT 400-M
transilluminator (IBI Kodak, NY), the resulting densitometric
signals were analyzed using ImageJ software (National Institutes of
Health) and presented as a ratio of HN/b-actin [25,27].
In Situ Detection of Apoptosis by Terminal
Deoxynucleotidyl Transferase-Mediated dUTP Nick
End-Labeling (TUNEL) Assay
Apoptosis was evaluated by the TUNEL method using a
commercially available kit (ApoptagH Peroxidase In-Situ Apopto-
sis Detection Kit; Chemicon) [28] according to the vendor’s
instructions, as previously described [20,25], using rat mammary
gland tissue for positive control and omission of TdT enzyme as a
negative control. Methyl green (Vector Laboratories, CA) was
used for nuclear counterstain.
Immunofluorescent staining for HN, CD68, a-actinin,
vimentin, fascin, iNOS, and arginase 1
Immunofluorescence was used to detect the co-localization of
HN (rabbit anti-HN, UCLA, 1:250) with macrophages (mouse
anti-CD68, Dako, 1:100), smooth muscle cells (mouse anti-a-
actinin, Abcam, 1:100), fibroblasts (mouse anti-vimentin, Abcam,
1:100), and dendritic cells (mouse anti-fascin, Dako, 1:50), similar
to protocol previously described [8]. Primary antibodies were
pooled (HN+one cell marker) and incubated with the tissue
overnight at 4uC followed by 309 incubation with pooled
secondary antibodies the next day at room temperature (Alexa
Fluor 488 goat anti-rabbit IgG (H+L) and Alexa Fluor 568 goat
anti-mouse IgG (H+L), Invitrogen, 1:800). Slides were cover-
slipped with a DAPI-impregnated mounting medium (UltraCruz)
and stored in the dark at 4uC. Normal rabbit and mouse
immunoglobulin serum fractions were substituted for primary
antibodies as negative controls.
We further characterized what state of macrophage polarization
HN is associated with in regard to inducible nitric oxide synthase
(iNOS)-positive proinflammatory (M1) macrophages or arginase 1-
positive noninflammatory (M2) macrophages [29,30]. In plaque
sections stained with DAPI, single and double immunofluorescent
stainings were performed with HN (rabbit anti-HN, UCLA, 1:250)
and either iNOS (Santa Cruz, 1:100) or arginase 1 (Santa Cruz,
1:100) conjugated antibodies. The number of double positive cells
per field was quantified in 15–20 fields per slide which were then
averaged in each sample over the entire patient group. Images
were taken using a Zeiss LSM-510 confocal laser scanning
microscope (Carl Zeiss MicroImaging, Inc).
Immunofluorescent staining for MMP2 and MMP9
We also examined whether HN demonstrated co-localization
with certain metalloproteinases recognized as inflammatory
markers of plaque instability [8,31]. The procedure was the same
as described above with the exception of HN (rabbit anti-HN,
UCLA, 1:250) co-stained with either MMP2 (goat anti-MMP2,
R&D Systems, 1:100) or MMP9 (goat anti-MMP9, R&D Systems,
1:100) primary antibodies followed by different secondary
antibodies (Alexa Fluor 488 donkey anti-rabbit IgG (H+L) and
Alexa Fluor 594 donkey anti-goat IgG (H+L), Invitrogen, 1:800).
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Asymptomatic (n=12) Symptomatic (n=22) TIA (n=12) Stroke (n=10)
Age, y 73627 1 626 9 637 2 63
Sex M/F, n 8/4 13/9 8/4 5/5
BMI, kg/m
2 30.162.0 28.661.1 28.561.2 28.661.9
Systolic blood pressure, mm Hg 132.364.3 140.964.5 140.265.9 141.767.3
Diastolic blood pressure, mm Hg 68.462.2 77.261.7* 79.462.0* 74.762.7
Medical History
CAD, n (%) 9 (75) 5 (22)* 3 (25)* 2 (20)*
Hypertension, n (%) 11 (92) 16 (73) 9 (75) 7 (70)
Diabetes, n (%) 2 (17) 3 (14) 2 (17) 1 (10)
Smoking History, n (%) 7 (58) 17 (77) 9 (75) 8 (80)
Hypercholesterolemia, n (%) 9 (75) 13 (59) 8 (67) 5 (50)
Lipid Profile
Total Cholesterol, mg/dL 189.4610.4 187.167.5 183.668.0 192.0614.8
LDL, mg/dL 109.267.4 107.367.5 103.469.4 112.9613.0
HDL, mg/dL 44.463.3 42.962.4 41.563.5 44.963.1
Medications
Statins, n (%) 7 (58) 7 (32) 4 (33) 3 (30)
ACE-Inhibitors, n (%) 3 (25) 4 (18) 4 (33) 0 (0)
ARBs, n (%) 1( 8) 2 (9) 1 (8) 1 (10)
Aspirin, n (%) 10 (83) 19 (86) 12 (100) 7 (70)
Days since last event 0607 9 621 71627 85635
BMI indicates body mass index; CAD indicates coronary artery disease; LDL indicates low density lipoprotein; HDL indicates high density lipoprotein; ARB indicates
angiotensin II receptor blocker; Values are expressed as mean6SEM for continuous variables;
*p,0.05 vs. asymptomatic.
doi:10.1371/journal.pone.0031065.t001
Figure 1. Histological immunoreactivity of HN is greater in symptomatic patients. HN expression is greater in carotid plaques from TIA
(n=12) and stroke (n=10) symptomatic patients than in asymptomatic patients (n=12; {p,0.001).
doi:10.1371/journal.pone.0031065.g001
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Statistical analysis was performed between groups using the t
test for continuous variables and Fisher’s exact test for categorical
variables. Data is presented as either mean6SEM or percentage.
Differences were considered significant when p,0.05.
Results
Of the 34 patients included in this study, 22 were symptomatic
and 12 were asymptomatic. Of the symptomatic patients, 12 had
TIAs and 10 had strokes. There were no major differences in
demographics between groups except that the symptomatic group
(both TIA and stroke) had a higher average diastolic blood
pressure and a lower prevalence of CAD compared to the
asymptomatic group (see Table 1).
HN is differentially expressed among clinically
categorized plaques
The presence of HN was greater in the unstable plaques of
symptomatic patients (Figure 1). Immunostaining and quantifica-
tion of carotid plaques demonstrated higher levels in the
symptomatic group compared to the asymptomatic group
(29.4262.05 vs. 14.1462.13% of plaque area, p,0.0001). The
increased amount of HN in the symptomatic group was attributable
equally to the TIA and stroke subgroups (Figure 1; 29.0063.18 and
29.9262.60%, respectively, p,0.001). HN seemed to be diffusely
localized throughout the plaque, most notably in regions of
increased cellularity (Figure 2). This data obtained from histology
was further confirmed by Western blot analysis. The expression of
HN in the plaque was greater in the symptomatic group compared
to the asymptomatic group (density ratio of HN/b-actin 1.3260.14
vs. 0.7960.11, p,0.01). In this case, the TIA subgroup was
significantly greater than the asymptomatic group (Figure 3; density
ratio of HN/b-actin 1.3560.23 vs. 0.7960.11, p,0.05) while the
stroke subgroup showed a trend (density ratio of HN/b-actin
1.2860.17 vs. 0.7960.11, p=0.08). Interestingly, linear regression
of the symptomatic plaque data revealed increased expression of
HN correlating with the number of days since the ischemic event
(,5% increase in HN staining per 100 days after the event,
R=0.50, p=0.03, data not shown). Similarly, we found that
TUNEL staining revealed a higherproportionof apoptoticnucleiin
these same plaques of symptomatic patients compared to asymp-
tomatic (Figure 4; 68.2563.61 vs. 33.4664.46% of nuclei, p,0.01).
HN is localized to cells of the atherosclerotic plaque
notably involved with an inflammatory state
Immunostaining revealed intracellular localization of HN with
light microscopy. To ascertain which cells are contributing to the
Figure 2. Representative immunostaining of HN. HN can be seen in carotid plaques (top row) from asymptomatic (left), TIA (middle), and
stroke (right) patients. Increased magnification of these slides (bottom row) demonstrates intracellular localization (arrows indicate exampleso f
staining).
doi:10.1371/journal.pone.0031065.g002
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symptomatic patients than in asymptomatic patients (combined symptomatic not depicted, p,0.01). Representative immunoblot shown above.
Results expressed as the ratio of HN and b-actin densitometric signals ({p,0.05 vs. asymptomatic).
doi:10.1371/journal.pone.0031065.g003
Figure 4. Cellular apoptosis is greater in plaques of symptomatic patients. Representative TUNEL staining can been seen in carotid plaques
from (A) asymptomatic and (B) symptomatic patients. Inserts show magnification of the black boxes in the main figure and arrows indicate brown
apoptotic nuclei (original magnification 2006). Proportion of apoptotic nuclei was greater in plaques of symptomatic patients compared to
asymptomatic (p,0.01).
doi:10.1371/journal.pone.0031065.g004
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cence labeling and confocal microscopy to visualize the co-
localization of HN with known cell markers. HN was co-expressed
with CD68(+) macrophages, a-actinin(+) smooth muscle cells,
vimentin(+) fibroblasts, and fascin(+) dendritic cells (Figure 5).
In addition, HN was found to be expressed in both M1 and M2
phase macrophages. Interestingly, the presence of proinflamma-
tory M1 macrophages co-stained with HN was greater in
symptomatic patients compared with asymptomatic patients
(Figures 6 and 7; p,0.05). However, no significant difference
was noted among patient groups for HN-positive M2 macrophag-
es. Along with these findings, MMP2 was co-localized with HN in
the intima and media, while MMP9 was predominant mostly in
the media (Figure 8).
Discussion
The current study demonstrates for the first time that the HN
protein is present in carotid atherosclerotic plaques and that its
expression is greater in patients with symptomatic disease
compared to those with asymptomatic disease. The immunoreac-
tivity of HN for both blotting and staining was nearly two-fold in
the symptomatic group than that of the asymptomatic group.
Additionally, we found the amount of apoptosis in these
symptomatic plaques is greater, consistent with prior studies
demonstrating that factors involved with the progression and
instability of the atheromatous plaque (such as inflammation,
reduction of proteosome activity, and oxidative stress) correlate
with a symptomatic history involving an ischemic event [8,12,25].
A large body of evidence supports the propensity of unstable
plaques to result in significant, possibly life-threatening, clinical
manifestations and the characteristics of these vulnerable plaques
have been described extensively [32,33,34]. Consequently, studies
investigating cytoprotection and mitigating the potentially adverse
effects of apoptosis (in regard to both endothelial dysfunction and
the late-stage necrotic atheroma) as a means to prevent
atherosclerotic complications may be of considerable value
[13,35,36,37]. The beneficial effect of inhibiting apoptosis in
atherosclerosis is controversial, however, as it may alternatively
help reduce cellularity of early plaque lesions in conjunction with
efferocytosis [38]. Given these observations we present here an
endogenously expressed peptide in the atherosclerotic plaque that
is widely shown elsewhere to have cytoprotective properties with a
notable role of preventing apoptosis.
Evidence of these properties have been seen in CNS neurons
[39,40], cerebrovascular smooth muscle cells [41], testicular germ
cells [18,42], pancreatic beta cells [21], and skeletal muscle cells
[19]. HN is found to modulate cellular apoptosis by binding
Figure 5. HN is localized to multiple cells of the atheromatous plaque. Immunofluorescence of the carotid plaque to detect the presence of
(A) HN with (B) CD68. (C) Nuclei can be visualized using a DAPI counterstain. (D) Merging of these images demonstrates co-localization of HN with
plaque macrophages, (E) seen better with increased magnification. Merged images below demonstrate co-localization of HN with (F) smooth muscle
a-actinin, (G) fibroblast vimentin, and (H) dendritic cell fascin.
doi:10.1371/journal.pone.0031065.g005
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tion to the mitochondrion, preventing the subsequent release of
cytochrome c into the cytosol [43,44,45]. HN also binds and
antagonizes the pro-apoptotic molecule IGFBP-3 and binds an
extracellular membrane receptor (composed of the CNTF-R,
WSX-a, and GP130 subunits), which subsequently activates the
JAK2/STAT3 pathway [46,47,48,49,50,51]. Because studies have
demonstrated that it can protect against memory impairment and
ischemic injury [52,53], HN and synthetic HN-analogues are
currently under investigation as Alzheimer’s disease treatments
[49,54,55]. Interestingly, HN has also been shown to be a
metabolo-protective factor and is able to normalize blood sugar in
diabetic ZDF rats through a hypothalamic mechanism involving
STAT3 activation [56].
The role of HN in the cardiovascular system is also now
emerging. HN decreases the myocardial infarct size in an
experimental model of ischemia and reperfusion in mice [22]
and prevents ROS production and death of human aortic
endothelial cells exposed to Ox-LDL [20]. The latter is of note
because Ox-LDL itself results from the penetration of LDL across
the damaged endothelial cell layer into the subendothelial space
where it is converted by ROS produced from endothelial and
smooth muscle cells. Ox-LDL then propagates the formation of
ROS leading to oxidative stress, inflammation, and the formation
of atherosclerotic plaque [57,58,59]. Thus, the histological finding
of HN in the plaque extends our previous observations and
supports a potential role for HN in atherosclerosis, possibly as an
endogenous response to the inflammatory and apoptotic processes
within the atheromatous plaque.
At present, the mechanism leading to higher expression of HN
in plaques of symptomatic patients remains speculative, particu-
larly because progression of the atheromatous plaque is multifac-
torial. One possibility is that HN is being produced as part of an
injury response mechanism. Since apoptosis is a natural process in
late-stage atherosclerosis contributing to formation of a necrotic
core and unstable plaque, the expression of HN might be a defense
mechanism to slow progression of the disease. But since unstable
plaques demonstrate higher levels of HN, this compensatory
response may not be sufficient to withstand sustained insult and
consequently, eventual ischemic events result. Another possibility
Figure 6. HN is expressed in M1 phase macrophages. Immunofluorescence reveals the presence of more HN-secreting macrophages in the M1
polarization phase (indicated by iNOS) in symptomatic patients (*p,0.05 vs. asymptomatic, #p,0.05 vs. TIA).
doi:10.1371/journal.pone.0031065.g006
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plaques following stroke, a process notably associated with the
decrease of caspase-3, a marker of apoptosis [60,61]. Our finding
that HN in the plaque modestly increases with time after an
ischemic event may be associated with this. Further investigation
correlating markers of apoptotic pathways in the carotid plaque
with the expression of HN, particularly with those that bind HN
directly including the pro-apoptotic molecule IGFBP-3 and
extracellular JAK2/STAT3 pathway membrane receptor (com-
posed of the CNTF-R, WSX-a, and GP130 subunits) [46,47,50],
may help answer these questions.
We also demonstrated intracellular expression of HN in
macrophages, smooth muscle cells, fibroblasts, and dendritic cells
(it should be noted that distinguishing smooth muscle cells from
fibroblasts may be difficult in certain instances because myofibro-
blasts are reported in the atherosclerotic plaque) [62,63]. A couple
of observations in the literature are consistent with these findings:
1) exogenous HN has been shown to prevent apoptosis in smooth
muscle cells of CNS vasculature [41] and 2) HN acts as an agonist
on the formyl peptide receptor-like 2 (FPRL2) found on the
extracellular membrane surface of macrophages and dendritic
cells [64,65]. Moreover, HN originates from the mitochondrial
genome, which may explain its ubiquitous expression [39]. In
addition, HN was found to be expressed by both states of
macrophage polarization, though predominantly more expressed
by proinflammatory M1 macrophages in symptomatic patients.
HN also co-localized with MMP2 and MMP9, inflammatory
markers with the ability for enzymatic remodeling of the fibrous
cap as well as signaling vascular smooth myocytic migration [31].
Taken together, these data suggest that these infiltrating cells of the
Figure 7. HN is expressed in M2 phase macrophages. HN-secreting macrophages in the M2 polarization phase (indicated by arginase-1) were
present, but less in number than HN-secreting M1 macrophages. No differences were seen between groups.
doi:10.1371/journal.pone.0031065.g007
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effects via an intracellular, autocrine, and/or paracrine mecha-
nism, possibly involving the mitochondrial oxidative/apoptotic
response to oxidant-induced mitochondrial dysfunction in athero-
genesis [20,39,66,67]. In line with this, recent reports have
discussed the possibility of mitochondria-specific antioxidative
mechanisms to treat atherosclerosis by decreasing mitochondrial
damage and permeability [68,69]. This ultimately would inhibit
cytochrome c release and oxidant-induced apoptosis, interestingly
the same net benefit imparted by the mitochondrial-derived
peptide, HN [43,44,45,48,49,70].
In summary, the current study demonstrates that HN is present
in carotid atherosclerotic plaques and that its higher expression is
associated with cellular apoptosis and a clinical symptomatic
history of ischemia. Moreover, we were able to localize its
expression within various cells of the plaque, notably those
associated with states of inflammation. These data support a role
for HN in atherosclerosis.
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